cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Arvinas Inc
6 own
4 watching
Current Price
$0
$-0.64
(-2.66%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,282.13M
52-Week High
52-Week High
58.58
52-Week Low
52-Week Low
21.21
Average Volume
Average Volume
0.44M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,282.13M
icon52-Week High58.58
icon52-Week Low21.21
iconAverage Volume0.44M
iconDividend Yield--
iconP/E Ratio--
What does the Arvinas Inc do?
Arvinas, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company's lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer. It is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. The company has a collaboration with Bayer AG to develop novel proteolysis-targeting chimera candidates for humans and plants. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.
Read More
How much money does Arvinas Inc make?
News & Events about Arvinas Inc.
Globe Newswire
1month ago
Multiple vepdegestrant (ARV-471) studies enrolling globally, including Phase 1, 2, and 3 studies Preliminary data from the Phase 1b combination trial of vepdegestrant + palbociclib suggests potential clinical benefit in a heavily pretreated patient population NEW HAVEN, Conn., May 05, 2023 (GLOBE ...
PR Newswire
1month ago
Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform...
Ticker Report
1month ago
Arvinas, Inc. (NASDAQ:ARVN Get Rating) has been given a consensus rating of Moderate Buy by the eighteen brokerages that are covering the company, Marketbeat reports. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The...
Accesswire
2 months ago
Oerth's unique PROTAC® protein degradation technology is expected to be a new, game-changing generation of more sustainable crop protection products / The agreement recommits to the combination of Oerth Bio's specialized expertise designing PROTAC® degraders for agriculture with...
Zolmax
3 months ago
Arvinas, Inc. (NASDAQ:ARVN Get Rating) Equities researchers at HC Wainwright issued their Q2 2023 earnings estimates for Arvinas in a research report issued to clients and investors on Friday, February 24th. HC Wainwright analyst A. Fein forecasts that the company will post earnings ...
Frequently Asked Questions
Frequently Asked Questions
What is Arvinas Inc share price today?
plus_minus_icon
Can Indians buy Arvinas Inc shares?
plus_minus_icon
How can I buy Arvinas Inc shares from India?
plus_minus_icon
Can Fractional shares of Arvinas Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Arvinas Inc stocks?
plus_minus_icon
What is today’s traded volume of Arvinas Inc?
plus_minus_icon
What is today’s market capitalisation of Arvinas Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Arvinas Inc?
plus_minus_icon
What percentage is Arvinas Inc down from its 52-Week High?
plus_minus_icon
What percentage is Arvinas Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.64
(-2.66%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00